The maker of Tylenol is urging US health regulators not to add an autism warning label to it and other pain relievers containing acetaminophen.

Kenvue stock has recently seen its consensus analyst price target decrease modestly from $21.70 to $20.63. This slight adjustment reflects a mix of new insights, as analysts weigh fresh legal and ...

Albert Invent announced in early 2025 a multi-year partnership with Kenvue Inc. to integrate advanced AI models into Kenvue’s global R&D processes, aiming to streamline and accelerate product ...

The severe stress caused by family upheaval might tax a child's immune system in ways that increase their chances of ...

The cost of employer-provided health insurance has surged for a third year, with the annual cost of a family plan approaching ...

3News launched a one hour noon news on Oct. 20 and The Daily Dose of Health News with Monica Robins is featured every day, ...

President Trump leafed through the MAHA report moments before its public release, scanning the document that laid the blame ...

MJH Life Sciences acquired BPD Healthcare, a 2025 MM+M Agency 100 honoree. Kenvue said it told the FDA its labeling request is unsupported by scientific evidence and would mark a departure from the ...